TRF effectively reduced systolic BP, mean BP, diastolic BP, and BW; improved hypertension-induced cardiac structural and functional damage; and inhibited the ACE-Ang-II-AT1 axis in circulating and LV tissues. The gene discussed is AGTR1; the disease is hypertensive disorder.